SENTI-202
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sorting 6 by
UCLA Medical Center of Hematology/Oncology
Los Angeles, CA
- Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Accepting patients
- Accepting patients
Center of Excellence
- Accepting patients
Methodist Hospital
San Antonio, TX
- Accepting patients
Center of Excellence
Mayo Clinic (Jacksonville)
Jacksonville, FL
- Not yet accepting
518 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.